证券代码：600216 证券简称：浙江医药 公告编号：2025-013 浙江医药股份有限公司 第十届四次监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 浙江医药股份有限公司第十届四次监事会会议于 2025 年 4 月 23 日上午在浙 江医药总部 1 号楼 401 会议室召开。本次会议的通知于 2025 年 4 月 3 日以专人 送达或电子邮件方式发出。会议应参加监事五人，实际参加监事五人。会议由监 事会主席李哲先生主持，会议符合《公司法》和《公司章程》的有关规定和要求。 二、监事会会议审议情况 1. 审议通过了《公司 2024 年度监事会工作报告》 同意 5 票，反对 0 票，弃权 0 票。 3．审议通过了《公司 2024 年度利润分配预案》 同意 5 票，反对 0 票，弃权 0 票。 监事会认为，公司 2024 年度利润分配预案的决策程序、利润分配的形式符 合《公司章程》。此利润分配预案充分考虑各方面因素，不存在损害中小股东利 益的情形，符合公司经营现状，有利于公司持续、稳定、 ...

证券代码：600216 证券简称：浙江医药 公告编号：2025-012 浙江医药股份有限公司 二、会议审议情况 1. 董事会审议通过了《公司 2024 年度董事会工作报告》 同意 11 票，反对 0 票，弃权 0 票。 本议案需提交股东大会审议。 2．董事会审议通过了《公司 2024 年度总裁工作报告》 同意 11 票，反对 0 票，弃权 0 票。 第十届五次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 浙江医药股份有限公司第十届五次董事会会议于 2025年 4 月 23 日上午在浙 江医药总部 1 号楼 401 会议室，以现场结合通讯表决的方式召开。本次会议的通 知于 2025 年 4 月 3 日以专人送达或电子邮件方式发出。会议应参加董事十一人， 实际参加董事十一人，其中董事苍宏宇先生通过通讯表决方式出席会议。会议由 公司董事长李男行先生主持，公司监事及其他高级管理人员列席会议，会议符合 《公司法》和《公司章程》的有关规定和要求。 本议案需提交股东大会审议。 4．董事会审议通 ...

浙江医药股份有限公司 证券代码：600216 证券简称：浙江医药 公告编号：2025-014 2024 年年度利润分配方案公告 公司拟向全体股东每股派发现金红利0.37元（含税）。截至2024年12月31 日，公司总股本961,637,750股，以此计算合计拟派发现金红利355,805,967.50 元（含税）。本年度公司现金分红占2024年度归属于上市公司股东净利润的比例 30.66%。 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：每股派发现金红利 0.37 元（含税） 本次利润分配以实施权益分派股权登记日登记的总股本，扣除回购专 用证券账户中累计回购的股份为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分配比例不 变，相应调整分配总额，并将在相关公告中披露。 不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以下简 称《股票上市规则》）第 9.8.1 条第一款第（八）项规定的可能被实施其他风险 警示的情形。 一、 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 2,255,389,182.25, a slight increase of 0.28% compared to CNY 2,249,164,467.20 in the same period last year[5] - Net profit attributable to shareholders reached CNY 409,085,292.06, representing a significant increase of 273.08% from CNY 109,649,638.31 year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 402,222,697.47, up 279.23% from CNY 106,062,788.51 in the previous year[5] - Basic and diluted earnings per share were both CNY 0.43, reflecting a 290.91% increase from CNY 0.11 in the previous year[5] - The weighted average return on equity rose to 3.77%, an increase of 2.64 percentage points from 1.13% year-on-year[5] - Total operating revenue for Q1 2025 was CNY 2,255,389,182.25, a slight increase of 0.6% compared to CNY 2,249,164,467.20 in Q1 2024[16] - Net profit for Q1 2025 reached CNY 385,252,415.30, a substantial increase of 385.5% compared to CNY 79,363,327.86 in Q1 2024[17] - Other comprehensive income after tax for Q1 2025 was CNY 9,122,458.68, compared to a loss of CNY 3,950,569.56 in Q1 2024[17] - The total comprehensive income for Q1 2025 was CNY 394,374,873.98, significantly higher than CNY 75,412,758.30 in Q1 2024[17] Cash Flow - The net cash flow from operating activities was CNY 304,964,651.00, a remarkable increase of 1,216.17% compared to CNY 23,170,551.20 in the same quarter last year[5] - Cash flow from operating activities generated a net amount of CNY 304,964,651.00, a significant increase from CNY 23,170,551.20 in Q1 2024[19] - The net cash flow from investment activities was -$118.42 million, a decrease from $57.78 million in the previous period[20] - Cash inflow from financing activities totaled $185 million, down from $285 million year-over-year[20] - The net cash flow from financing activities was $42.23 million, slightly down from $43.28 million in the previous period[20] - The net increase in cash and cash equivalents was $251.60 million, compared to $124.27 million in the previous period[20] - The ending balance of cash and cash equivalents was $2.22 billion, up from $1.58 billion year-over-year[20] - Cash received from investment activities amounted to $472.92 million, compared to $470.62 million in the previous period[20] - Cash outflow for investment activities was $591.34 million, an increase from $412.85 million in the previous period[20] - Cash received from loans was $185 million, down from $285 million in the previous period[20] - Cash paid for debt repayment was $137 million, compared to $235 million in the previous period[20] - The impact of exchange rate changes on cash and cash equivalents was $22.83 million, compared to $44.69 thousand in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 13,996,653,397.63, up 1.46% from CNY 13,795,473,105.69 at the end of the previous year[6] - The equity attributable to shareholders increased to CNY 11,067,801,751.72, a growth of 3.94% from CNY 10,648,142,085.06 at the end of last year[6] - The company's current assets totaled RMB 6,811,951,484.56, compared to RMB 6,584,941,036.57 at the end of the previous period, reflecting a growth of approximately 3.45%[13] - Cash and cash equivalents increased to RMB 2,217,402,229.72 from RMB 1,965,821,411.06, representing a growth of about 12.83%[12] - Accounts receivable rose to RMB 1,709,971,371.66, up from RMB 1,627,259,114.94, indicating an increase of approximately 5.06%[12] - The company's total liabilities decreased to RMB 2,730,687,092.79 from RMB 2,927,530,865.79, a reduction of about 6.71%[14] - The equity attributable to shareholders increased to RMB 11,067,801,751.72 from RMB 10,648,142,085.06, marking an increase of approximately 3.93%[14] - The company's inventory decreased to RMB 2,039,510,754.71 from RMB 2,132,515,095.23, reflecting a decline of about 4.36%[12] Other Financial Metrics - The increase in net profit was primarily driven by the rise in sales prices of Vitamin E and Vitamin A series products compared to the same quarter last year[8] - The company reported non-recurring gains totaling CNY 6,862,594.59, which included various government subsidies and asset disposal gains[8] - The company reported an investment income of CNY 8,080,460.07, recovering from a loss of CNY 1,500,647.53 in the previous year[16] - Research and development expenses for Q1 2025 were CNY 177,463,871.00, a decrease of 9.5% from CNY 196,215,236.98 in Q1 2024[16] - The company experienced a decrease in sales expenses to CNY 240,680,661.64, down from CNY 288,699,872.16 in the same quarter last year[16] - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[12] - The long-term investments stood at RMB 74,404,761.76, showing stability compared to previous periods[13]

Financial Performance - Zhejiang Medicine's operating revenue for 2024 reached RMB 9,375,216,922.05, representing a 20.29% increase compared to RMB 7,794,145,971.37 in 2023[22]. - The net profit attributable to shareholders of the listed company surged to RMB 1,160,510,670.41, a significant increase of 170.11% from RMB 429,639,626.26 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was RMB 1,160,134,311.05, up 656.77% from RMB 153,300,563.21 in 2023[22]. - The net cash flow from operating activities for 2024 was RMB 1,223,298,641.95, reflecting a 92.85% increase from RMB 634,311,163.34 in 2023[22]. - As of the end of 2024, the net assets attributable to shareholders of the listed company were RMB 10,648,142,085.06, a 10.56% increase from RMB 9,630,715,541.49 at the end of 2023[22]. - Total assets increased by 7.95% to RMB 13,795,473,105.69 at the end of 2024, compared to RMB 12,779,539,756.21 at the end of 2023[22]. - Basic earnings per share increased by 168.89% to CNY 1.21 from CNY 0.45 in 2023[23]. - Diluted earnings per share also rose by 168.89% to CNY 1.21 compared to CNY 0.45 in 2023[23]. - The weighted average return on equity increased by 6.89 percentage points to 11.43% from 4.54% in 2023[23]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 0.37 per share, totaling RMB 355,805,967.50, which represents 30.66% of the net profit attributable to shareholders for 2024[6]. - The company executed the 2023 profit distribution plan in July 2024, distributing a cash dividend of CNY 355,805,967.50, which accounts for 30.66% of the net profit attributable to ordinary shareholders[150]. - The cumulative cash dividend amount over the last three accounting years is CNY 664,097,380.00, with an average cash dividend ratio of 93.55% based on the average net profit of CNY 709,906,793.30[152]. Operational Highlights - The company has not reported any significant risks that could materially affect its operations during the reporting period[9]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[8]. - The company has a standard unqualified audit report from Tianjian Accounting Firm, ensuring the accuracy and completeness of the financial report[5]. - The company completed the trial production of the new process for the Changhai Biological 331 project, achieving expected goals[30]. - The subsidiary Laoyi Pharmaceutical reported a dual growth in sales and profits through optimized operational strategies[32]. - The company’s injection product Daptomycin (0.5g) received the drug registration certificate during the reporting period[30]. - The subsidiary Xinma Biological is advancing the production license application for the antibody-drug conjugate ARX788[32]. Market and Product Development - The company is focusing on innovation in drug development, particularly in innovative drugs and biotechnology, as the pharmaceutical industry shifts towards an innovation-driven model[33]. - The company is actively expanding its market presence in Southeast Asia while consolidating its position in Europe and North America[33]. - The company has established a comprehensive product system in the life nutrition sector, including synthetic vitamins E and A, with significant market positions in both domestic and international markets[35]. - The company is transitioning to an "Industry 4.0" model, implementing modern, digital control systems in production, including unmanned production lines and workshops[41]. - The company is focusing on developing innovative drugs to meet unmet clinical needs and creating generic drugs with certain technical barriers, adopting a "combination of generic and innovative" strategy for product pipeline differentiation[73]. Research and Development - The company’s R&D investment amounted to 79,568.92 million RMB, representing 7.10% of operating income and 7.16% of net assets[91]. - The company has established two technical platforms in the vitamin product field: industrial green chemistry and microencapsulation of active ingredients[85]. - There are currently 4 new drug projects under research, with 6 in clinical research or BE stages, and 10 production applications submitted[85]. - The company is currently conducting clinical trials for the new drug Apixaban, which targets urinary system infections with a new indication[86]. - The company has received IND approval for LYSC98, a Class 1 new drug for anti-infection, expected to launch in May 2024[86]. Environmental and Social Responsibility - The company has established an environmental protection mechanism and invested CNY 84,993,900 in environmental protection funds during the reporting period[158]. - The company has implemented pollution prevention facilities in compliance with environmental assessment requirements, including three RTO incinerators and various wastewater treatment systems[160]. - The company has developed emergency response plans for environmental incidents, which are filed with local ecological environment authorities and include annual drills[164]. - The company has achieved stable operation of its wastewater treatment systems, with all emissions meeting regulatory standards according to annual environmental monitoring reports[161]. - Total donations for social responsibility projects amounted to 2.82 million yuan, benefiting various educational foundations and charities[170]. Governance and Management - The company held one shareholders' meeting during the reporting period, ensuring equal treatment of all shareholders and compliance with legal requirements[117]. - The board of directors consists of 11 members, including 4 independent directors, and has established specialized committees to enhance governance[118]. - The supervisory board has 5 members, ensuring independent oversight of the company's operations and compliance with regulations[119]. - The company has implemented stock incentive plans, resulting in significant reductions in compensation for several executives, such as a decrease of 50,000 for the Vice President[124]. - The company is undergoing a leadership transition, with several key positions set to change by June 2024[124]. Risks and Challenges - The company faces risks from intensified market competition, which may lead to a decline in market share and profit margins[113]. - Rising production costs due to fluctuations in raw material prices and increased labor costs may impact profitability; the company plans to optimize supply chain management and improve production efficiency[113]. - The risk of new drug development failures exists, with high costs and long cycles; the company aims to enhance budget management and improve research quality through advanced management techniques[113]. - Investment in innovative biopharmaceuticals may face challenges in overseas market registrations, potentially extending the investment return period; the company will streamline internal processes to mitigate impacts on profitability[113].

目 录 | 一、审计报告……………………………………………………… 第 1—6 | | 页 | | --- | --- | --- | | 二、财务报表……………………………………………………… 第 7—14 | | 页 | | （一）合并资产负债表…………………………………………… 第 | 7 | 页 | | （二）母公司资产负债表………………………………………… 第 | 8 | 页 | | （三）合并利润表………………………………………………… 第 | 9 | 页 | | （四）母公司利润表………………………………………………第 | 10 | 页 | | （五）合并现金流量表……………………………………………第 | 11 | 页 | | （六）母公司现金流量表…………………………………………第 | 12 | 页 | | （七）合并所有者权益变动表……………………………………第 | 13 | 页 | | （八）母公司所有者权益变动表…………………………………第 | 14 | 页 | | | | 关键审计事项是我们根据职业判断，认为对本期财务报表审计最为重要的事 项。这些事项的应对以对财务报表整体进行审计并形 ...

目 录 一、内部控制审计报告…………………………………………第 1—2 页 内部控制审计报告 天健审〔2025〕7379 号 浙江医药股份有限公司全体股东： 第 1 页 共 2 页 范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是浙江 医药公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，浙江医药公司于 2024 年 12 月 31 日按照《企业内部控制基本规 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了浙江医药股份有限公司（以下简称浙江医药公司）20 ...

浙江医药股份有限公司 独立董事 2024 年度述职报告 报告人：吴以扬 作为浙江医药股份有限公司（以下简称"公司"）独立董事，本着为全体股 东负责的精神，严格按照《公司法》、《证券法》、《上市公司治理准则》、《上市公 司独立董事规则》等法律法规的规定和要求，并以《公司章程》和《公司独立董 事制度》为指引，忠实履行了独立董事职责，主动了解公司的经营情况，对重大 事项发表意见、提出建议，切实维护了公司及股东，尤其是中小股东的合法权益。 现将 2024 年度履职情况报告如下： 一、独立董事基本情况 （一）工作履历及专业背景 本人吴以扬，1962 年生，中共党员，华东政法大学法学学士，编审（教授）， 二级巡视员（副厅级）。1984 年 7 月至 2008 年 4 月在上海法治报工作，历任编 辑、记者、新闻采编中心主任、总编助理、副总编，曾获"全国百佳法制新闻工 作者"荣誉称号。2008 年 4 月至 2022 年 7 月在上海市法学会工作，历任会员部 副主任、《东方法学》杂志常务副主编、编辑部主任、研究部主任、二级巡视员， 曾获"全国优秀法学会工作者"荣誉称号。 （二）独立性情况说明 经过自查，我对自身的独立性情况进 ...

浙江医药股份有限公司 独立董事 2024 年度述职报告 报告人：裘益政 作为浙江医药股份有限公司（以下简称"公司"）独立董事，本着为全体股 东负责的精神，严格按照《公司法》、《证券法》、《上市公司治理准则》、《上市公 司独立董事规则》等法律法规的规定和要求，并以《公司章程》和《公司独立董 事制度》为指引，忠实履行了独立董事职责，主动了解公司的经营情况，对重大 事项发表意见、提出建议，切实维护了公司及股东，尤其是中小股东的合法权益。 现将 2024 年度履职情况报告如下： 一、独立董事基本情况 （一）工作履历及专业背景 本人裘益政，1974 年生，中共党员，博士研究生学历，教授。中国会计学 术高端人才，浙江省管理会计咨询专家，现任浙江工商大学会计学院党委书记。 2002 年 7 月至 2007 年 11 月任浙江工商大学讲师，2007 年 12 月至 2010 年 12 月 任浙江工商大学财务系主任，2011 年 1 月至 2019 年 12 月任浙江工商大学会计 学院副院长，2010 年 1 月至 2022 年 11 月任浙江工商大学金融学院党委书记。 2022 年 12 月至今任浙江工商大学会计学院党委书记 ...

浙江医药股份有限公司 独立董事 2024 年度述职报告 报告人：陈乃蔚 作为浙江医药股份有限公司（以下简称"公司"）独立董事，本着为全体股 东负责的精神，严格按照《公司法》、《证券法》、《上市公司治理准则》、《上 市公司独立董事规则》等法律法规的规定和要求，并以《公司章程》和《公司独 立董事制度》为指引，忠实履行了独立董事职责，主动了解公司的经营情况，对 重大事项发表意见、提出建议，切实维护了公司及股东，尤其是中小股东的合法 权益。现将 2024 年度履职情况报告如下： 一、独立董事基本情况 （一）工作履历及专业背景 本人陈乃蔚，1957 年生，法学博士，法学教授。1983 年至 1995 年任华东政 法大学经济法系教研室主任、副教授，1995 年至 2002 年任上海交通大学法律系 主任、教授，2002 年至 2015 年任上海市锦天城律师事务所高级合伙人，2005 年 至 2017 年任复旦大学法学院教授，2013 年至 2022 年 8 月任复旦大学高级律师 学院执行院长。2015 年至今任上海自贸区知识产权协会会长，2019 年至今任上 海仲裁协会监事长。 （二）独立性情况说明 经过自查，我对自身的独 ...